Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
The new hospital is expected to open by March'24
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
The partners also aim to expand their work to Latin America for the first time
Subscribe To Our Newsletter & Stay Updated
